Exposure to nanoparticles has presented potential risks to human cardiorespiratory systems. Pulmonary retention and extrapulmonary redistribution of inhaled nanoparticles have been considered to be important contributing factors of cardiorespiratory diseases. In the present work, 22-nm 59 Fe 2 O 3 nanoparticles (radioactive isotope 59 Fe-labeled ferric oxide nanoparticles) were intratracheally instilled into the male Sprague-Dawley rats at a dose of 4 mg/rat. Extrapulmonary distribution of 59 Fe 2 O 3 in organs and its metabolism in lung, blood, urine, and feces were measured for 50 days of exposure. Phagocytosis and clearance of agglomerated nano-Fe 2 O 3 by monocytes/macrophages were observed by histopathology and inductively coupled plasma-mass spectrometry examination. Our results showed intratrachealinstilled nano-59 Fe 2 O 3 could pass through the alveolar-capillary barrier into systemic circulation within 10 min that consisted with one-compartment kinetic model. The nano-59 Fe 2 O 3 in the lung was distributed to organs rich in mononuclear phagocytes, including liver, spleen, kidney and testicle. The plasma elimination half-life of nano-59 Fe 2 O 3 was 22.8 days and the lung clearance rate was 3.06 mg/day, indicating the systemic accumulation and lung retention had occurred. The deposited nano-Fe 2 O 3 in interstitial lung was probably contributed by the particles escaping from alveolar macrophages phagocytosis and macrophages clearance function overloading. Our results suggest that the effect of Fe 2 O 3 nanoparticles exposure, even at low concentration, should be assessed because of the potential lung and systemic cumulative toxicity of the nanoparticles.
A wealth of epidemiological and experimental studies indicate that exposure to airborne particulate matter has close association with increased morbidity and mortality from respiratory and cardiovascular diseases (Samet et al., 2000) .
Furthermore, ultrafine particles (UFPs) with aerodynamic diameter less than 100 nm in particulate matter were documented to be the crucial cause of cardiorespiratory disorders (Gamble and Lewis, 1996; Oberdörster et al., 2005; Stern and McNeil, 2008) . It is currently speculated that inhaled nano-scaled particles may escape from phagocytosis by lung alveolar macrophages and enter into the blood circulation (Nemmar et al., 2001) . Both cell culture and in vivo animal model studies indicated that the retention and the clearance processes were quite different between inhaled ultrafine and coarse particles (Ferin et al., 1992) . Among the findings of nanoparticles inhalation exposure, the impairment of pulmonary macrophage function, the decrease of monocytes/ macrophages phagocytic activity and mobility, and impairment of cytoskeleton were focused to be the important clearance dysfunctions of lung that induced nanoparticle deposition and accumulation (Barlow et al., 2008; Moeller et al., 2002) . The UFPs were demonstrated to be more toxic and inflammationgenerated than fine particles (Brown et al., 2001; Kuschner et al., 1997) , suggesting that the accumulation of nanoparticles in biological system was a most essential risk factor of nanotoxicity.
Among the increasing results of nanotoxicity, pulmonary retention and systemic redistribution of inhaled particles were considered to be the important contributing factors of cardiorespiratory diseases (Ferin et al., 1992) . Many studies on the direct effects of UFPs on systemic distribution found that UFPs might diffuse directly from the alveoli into the microvascular bed (Kato et al., 2003; Nemmar et al., 2001 Nemmar et al., , 2002a . However, the particokinetics and mechanisms involved in cardiorespiratory disturbance and potential toxicity by nanoparticle inhalation exposure are still seldom investigated.
Iron nanomaterials are considered to have a wide potential of applications in nanotechnology related fields including biomedical imaging, magnetic target drug delivery, environmental catalysis, magnetic storage and so forth (Hood, 2004) . Iron compounds are also highly exposed in miner areas, manufacturing and occupational workplaces for magnetopneumography users and welders. In view of these environmental and biomedical applications, the in vivo behavior of iron nanomaterials needs to be studied. Previous studies have demonstrated that inhaled iron particles would cause cardiorespiratory toxicities, such as siderosis (iron deposit in lung), hemochromatosis, and beta-thalassemia (Brittenham et al., 1994; Horwitz and Rosenthal, 1999; Olson et al., 1987) by iron overloading. Inhalation of iron particles in rats might cause oxidative stress and proinflammatory states in lung (Zhou et al., 2003) . Our previous studies showed that intratracheally instilled ferric oxide nanoparticles in rats could induce pulmonary inflammation, microvascular permeability increase and prolonged blood coagulation time (Zhu et al., 2008) . Critical kinetic parameters, such as blood circulation particokinetics parameters and pulmonary clearance rate, organ biodistribution and accumulation are essential for the mechanism if study of nanoparticle exposure involved in cardiorespiratory diseases. However, knowledge about its toxic mechanism is still scarce.
In the present study, a radioactive labeled, 22-nm-sized 59 Fe 2 O 3 particle suspension solution was intratracheally instilled into rats to identify the particokinetic profile of inhaled Fe 2 O 3 nanoparticles in vivo. We tested the hypothesis that the exposed Fe 2 O 3 nanoparticles could rapidly transfer from aveoli into systemic circulation. The blood circulation and elimination half-life, pulmonary retention, extrapulmonary translocation and metabolism of Fe 2 O 3 nanoparticles were studied to elucidate the potential risks involved in pulmonary and cardiovascular diseases. The phagocytosis and clearance of Fe 2 O 3 nanoparticles by monocytes and macrophages were tested by in vivo and in vitro study. The dissolution of Fe 2 O 3 nanoparticles in artificial tissue fluids was determined to evaluate the particle form and status in organs. The toxicity and the potential health risk assessment of Fe 2 O 3 nanoparticles exposure were accordingly desirable.
MATERIALS AND METHODS
Fe 2 O 3 particles. Fe 2 O 3 nanoparticles were purchased from Nanjing Haitai Nanomaterial Co., Ltd, Beijing, China. The size of particle was measured by transmission electron microscopy (TEM, JEM 200CX) (Fig. 1) . The purity of the materials was determined by inductively coupled plasma atomic emission spectrometry (ICP-AES, Baird ICP2070, Bedford, MA). The crystal structure of the Fe 2 O 3 nanoparticles was determined by X-ray diffraction analysis (PANalytical's X'Pert PRO, Almeo, the Netherlands). The specific surface area was measured by gas adsorption technique method using a surface area analyzer (Autosorb-1 model, Quantachrome, Boynton Beach, FL). The particle size distribution in cell culture medium, Dulbecco's modified Eagle's medium (DMEM, Gibco BRL) with 10% serum, was tested by dynamic light scattering (DLS) measurements (90 Plus Particle Size Analyzer, Brookhaven Instruments Corp., Holtsville, NY). The detailed properties of Fe 2 O 3 nanoparticles are shown in Table 1 . For the metabolic study, Fe 2 O 3 nanoparticles were irradiated in a heavy water nuclear reactor (China Institute of Atomic Energy, Beijing, China) at a neutron flux of 5 3 10 13 n/cm 2 Ás À1 for 7 days. After 2 weeks of decay, the 59 Fe 2 O 3 nanoparticles were dispersed in a saline solution at a concentration of 100 mg/ml, and then sonicated for 10 min and vortexed for 5 min before intratracheal instillation.
Animal treatment. Male Sprague-Dawley (SD) rats (body weight 250 ± 10 g) were obtained from the Experimental Animal Center, Peking University, and housed individually in metabolism cages in a climate-controlled room (20 ± 2°C, 50%-70% relative humidity) with a 12-h light/dark cycle, fed with commercial pellet diet and deionized water ad libitum. After 1-week acclimation, rats were divided into six experimental groups randomly. Eight rats were used in each treated group. Four experimental groups were treated with radioactive 59 Fe 2 O 3 nanoparticles for metabolism investigation, the other two groups were used for histopathological and transmission electron microscopy (TEM) observation. All the animal studies were approved according to the Ethics Committee of Animal Care and Experimentation of the National Institute for Environmental Studies, China. Fe 2 O 3 nanoparticles in lung and blood of rats was evaluated for 50 days after instillation. The lung clearance kinetics was evaluated using zero-order kinetics model. The correlation coefficient was 0.862. For blood particokinetics, the graph of the blood data in semi-log plot revealed a first-order absorption and a first-order elimination phase. The correlation coefficients were 0.980 and 0.997, respectively. According to the one-compartment model, the particokinetic parameters in blood were calculated. Figure 2 illustrates the particokinetic model we used in this study.
Transmission electron microscopy. For TEM study, at days 7 and 30 postinstillation, rats were anaesthetized and the lung tissues were removed and washed twice with saline. Subsequently, the lung tissues were cut into~1 mm 3 piece and immediately fixed in 2.5% glutaraldehyde overnight. The samples were treated according to the general protocols for TEM study. The ultrathin sections (70-100 nm) were stained with lead citrate and uranyl acetate and the specimens were viewed under a JEOL JEM-100CX II electron microscopy (Tokyo, Japan).
Histopathological examination. For histopathological examination, at day 7 or 30 postinstillation, rats were anesthetized and the lungs were collected and immediately immersed into 10% formaldehyde. A small piece of lung tissue was embedded into paraffin wax, then sectioned into 5-lm-thick slice and mounted on a glass microscope slide using the standard histopathological techniques (Xu et al., 2003) . The slices were stained with hematoxylin-eosin (HE) and examined by a light microscopy.
Macrophages (RAW264.7 cell line) and monocytes (U937 cell line) culture and exposure to Fe 2 O 3 nanoparticles. Monocyte and macrophage are the most commonly used cell-lines for phagocytosis investigation of inhaled nanoparticles (Geiser et al., 2008) . In the present study, RAW264.7 cell, a mouse macrophage cell line established from the ascites of a male BALB/c mouse, was used for the dissolution study of Fe 2 O 3 nanoparticles by macrophage phagocytosis.
The RAW264.7 cells were purchased from Cell Culture Center (CCC) of the Chinese Academy of Medical Sciences. Cells were cultured at 37°C in a humid atmosphere of 5% CO 2 in air in DMEM (Gibco BRL) supplemented with 100 U/ml penicillin G, 100 lg/ml streptomycin and 10% fetal bovine serum (FBS, Hyclone, Logan, UT). The 10 lg/ml Fe 2 O 3 nanoparticles were exposed in a standard six-well plate containing 2 ml of DMEM medium with confluent RAW264.7 monolayer for 48 h.
The U937 monocytic cell line was isolated from a 38-year-old female's malignant cells obtained from the pleural effusion. U937 monocytic cells were purchased from CCC of the Chinese Academy of Medical Sciences and were grown in suspension culture in PRMI 1640 medium supplemented with 100 U/ml penicillin G, 100 lg/ml streptomycin, and 10% FBS (Hyclone, Logan, UT). U937 cells were cultured at 37°C in a humid atmosphere of 5% CO 2 in air and maintained by replacement of fresh medium every 2 days. Cell density was maintained between 1 3 10 5 and 2 3 10 6 viable cells/ml. 0.2, 2, 20 lg/m Fe 2 O 3 nanoparticles were exposed in 0.5 ml of PRMI 1640 medium containing 2.5 3 10 5 cells per well for 24 h in a standard 12-well plate.
The two cells incubated free of nanoparticles were served as the control.
Assessment of Fe 2 O 3 particle solubility in artificial tissue fluids. In order to evaluate the solubility of the nanoparticles in tissue fluids, the dissolution of the Fe 2 O 3 nanoparticles in the saline solution (pH ¼ 7.2), artificial gastric fluid (pH ¼ 1) and artificial phagolysosomal fluid (pH ¼ 4.5) were measured. The simulant fluids were prepared according to the description in the previous work Woodhall et al., 2003) . According to the contents of particle in the metabolic study, the solubility of 100 lg/ml particle in saline solution, 1 mg/ml in gastric fluid and 2 lg/ml in phagolysosomal fluid were determined. A quantitative amount of 22 nm Fe 2 O 3 particles were ultrasonically dispersed and stirred at 37°C for 7 days, then the samples were centrifuged at 9168 g for 10 min and the supernatant was collected.
Inductively coupled plasma-mass spectrometry measurement of Fe 2 O 3 dissolution. The supernatant medium of RAW264.7 cells exposed for 1, 4, 24 and 48 h and U937 cells exposed for 6 and 24 h of Fe 2 O 3 nanoparticles were collected for inductively coupled plasma-mass spectrometry (ICP-MS; Elemental X7 ICP-MS, Thermo Electron Co., Waltham, MA) measurement. The exposed supernatant medium was centrifuged at 2292 g for 10 min to remove the suspended Fe 2 O 3 nanoparticles. The supernatant of the exposed simulant fluid was filtered through a 0.22-lm membrane. Then, each sample was digested and analyzed for Fe content. Briefly, prior to elemental analysis, the samples were digested in nitric acid (metal-oxide-semiconductor [MOS] grade, Beijing Chemical Reagent Research Institute) and hydrogen peroxide (H 2 O 2 , MOS grade, Beijing Chemical Reagent Research Institute) in a closed Teflon vessel at 160°C. Then the digested solution was transferred to a quartz beaker and heated at 120°C till almost one drop. Finally the remaining solutions were diluted to 2 ml with 2% nitric acid. The content of iron in the samples was determined by ICP-MS. The detection limit of Fe was about 0.057 ng/ml. Statistical analysis. All experimental results were expressed as means ± standard deviation. Statistical analyses of the results were performed by Student's t-test. A value of p < 0.05 was considered significant.
RESULTS
In the host lung tissue, the deposition of (Fig. 4) . Particles phagocytized by macrophages were observed in the pulmonary alveoli; moreover, nanoparticles appeared to be overloading to alveolar macrophages at the dose of 4 mg/rat instillation. The TEM images showed that the Fe 2 O 3 nanoparticles escaped from phagocytosis by alveolar macrophages and entered into alveolar epitheliums. A similar image could be observed at day 30 postinstillation (see Fig. 5 ). The dissolution of Fe 2 O 3 nanoparticles by macrophage phagocytosis was evaluated via exposure of Fe 2 O 3 nanoparticles in RAW264.7 cells. The exposed dose in the in vitro study was consistent with the Fe 2 O 3 dose in per alveolar macrophage of the intratrachealinstilled treatment. The results showed that with the ID in this study, after 48 h treatment, only 0.67 ± 0.02% Fe 2 O 3 nanoparticles had been dissolved (see Table 3 ).
The monocyte phagocytosis in circulation system was tested by the U937 cell exposure study. The cell density was chosen depending on the number of monocytes per ml human blood sample. The exposed dose was consistent with the 59 Fe 2 O 3 nanoparticle concentration in blood of the animal study (Fig. 6) . The concentration of dissolved Fe (ng/mL) and the percentage of Fe 2 O 3 nanoparticles dissolved in U937 culture medium are listed in Table 4 . The data showed that the dissolution of Fe 2 O 3 nanoparticles in monocytes was time and dose dependent. At the dose of 0.2 lg/ml Fe 2 O 3 after 6 h exposure, about 23% of Fe 2 O 3 was dissolved, whereas after 24 h exposure, almost 80% Fe 2 O 3 nanoparticle was dissolved. However, when the exposed dose was as high as 2-20 lg/ml Fe 2 O 3 nanoparticle, only more or less 10% nanoparticles was dissolved after 6 and 24 h exposure.
In the study, significant amount of 54.7 ± 16.5 ng/ml 59 Fe was rapidly found in blood within 10 min after instillation (Fig. 6) . The 59 Fe concentration in blood sharply increased in the first week to the highest value of about 6.05 ± 1.95 lg/ml after treatment, and then showed a very slow decrease with the subsequent time. At day 50 postinstillation, 0.75% of the initial 59 Fe still appeared in the blood (see Table 5 ). The extravascular administration of 59 Fe 2 O 3 blood concentration vs. time could be evaluated using a one-compartmental model and analyzed by method of residuals. Depending upon the 59 Fe blood particokinetics curve (Fig. 6) , the blood maximum concentration (C max ), time to achieve maximum concentration (T max ), absorption half-life (T 1/2K01 ), elimination half-life (T 1/ 2 K10 ), absorption constant (K 01 ), elimination constant (K 10 ), and area under curve (AUC inf ) were calculated (see Table 6 ). The data showed that after the single dose intratracheal exposure of 59 Fe 2 O 3 nanoparticles, the absorption half-life of 59 Fe in blood was as long as 1.9 day; the 59 Fe elimination half-life was longer than 22.8 day, in correspondence with the absorption and elimination constants as 0.363 and 0.030/day, respectively.
The extrapulmonary transported 59 Fe 2 O 3 was redistributed in many organs (Fig. 7) . The results shown in Figure 7 indicate that 59 Fe 2 O 3 can easily pass through a number of tissue compartments and accumulate in the extrapulmonary organs. The highest extrapulmonary 59 Fe levels were found in the liver, followed in the decreasing order: spleen, heart, kidney, pancreas, testicle and brain. The 59 Fe in the liver and heart showed time-response of accumulation from postinstilled day 1 to day 21, and then decreased at day 50. But in spleen, the 59 Fe showed persistent high level till to postinstilled day 50. Table 7 shows the percentage of accumulated 59 Fe in the organs at postinstilled day 50. The target extrapulmonary organs of 59 Fe were shown as organs rich in mononuclear phagocytes, such as the liver, spleen, kidney and testicle. The organ weights were consistent at all the time points (days 1, 7, 21, 50) of sacrificed rats except the significant decrease of lung tissue at postinstilled day 7 (p < 0.01, Table 2 ). 
The values represent mean ± SD (n ¼ 8). **Significant decrease comparing with the data at day 1 postinstillation (p < 0.01).
FIG. 3. Elimination kinetics of 59
Fe 2 O 3 in lung in 50 days postinstillation. The values represent mean ± SD (n ¼ 8).
KINETICS AND TRANSLOCATION OF NANO-FE 2 O 3
The intratracheal-instilled 59 Fe 2 O 3 was excreted in urine and feces. Figures 8 and 9 depict the excretion kinetic curves of 59 Fe in urine and feces after intratracheal exposure. The counts of 59 Fe in urine and feces increased with the postinstilled time and reached the peak concentrations of 0.81 ± 0.50 lg/ml at day 3 and 504 ± 143 lg/g at day 1 postinstillation, respectively. The counts of 59 Fe in urine decreased slowly after day 3 postinstillation, comparatively, 59 Fe in feces decreased at an extremely fast speed from postday 1. About 73.4% of the ID was excreted in feces during the whole 50 days postinstillation (see Table 5 ), whereas in day 1 the percentage of excretion was more than 68% (Fig. 9) . Comparatively, 0.7% of the ID was excreted in urine (see Table 5 ), whereas the highest value was found at day 3 postinstillation (Fig. 8) . The total amount of 26.8 and 2935 lg of instilled 59 Fe 2 O 3 were excreted in urine and feces during the 50 postinstilled days, respectively. The dissolution of Fe 2 O 3 nanoparticle in artificial tissue fluids showed that only 0.15 ± 0.03% nanoparticles dissolved in simulant gastric fluid. Interestingly, when the Fe 2 O 3 nanoparticles were exposed in the phagolysosomal simulant fluid, only 3.96 ± 0.47% of nanoparticles was dissolved, which was much lower than the value of the U937 phagocytotic analysis at the same dose. The dissolution of Fe 2 O 3 nanoparticles in the saline solution (pH 7.2). could not be detected (see Table 8 ).
DISCUSSION
Pulmonary retention, extrapulmonary translocation, and redistribution were considered to be the essential mechanisms of inhaled-nanoparticle induced cardiorespiratory diseases. The accumulated nanoparticles in the lungs might cause malignant   FIG. 4 . Histopathology of the treated or control lungs at days 7 and 30 after intratracheal instillation of particles or saline (HE stain). (A) control group (magnification ¼ 100); (B) at day 7 postinstillation (magnification ¼ 100), the black frame district was magnified as shown in figure (C); (C) Phagocytosis of agglomerated particles by alveolar macrophages at day 7 postinstillation (thin arrow, magnification ¼ 400); (D) at day 30 postinstillation (magnification ¼ 100), the black frame district was magnified as shown in figure (E); (E) phagocytosis of particles by alveolar macrophages at day 30 postinstillation (thin arrow, magnification ¼ 400). 346 effects to the lung structure with harmful consequences, involving lung inflammation, fibrosis and lung cancer (Brown et al., 2001; Oberdörster et al., 2005; Xu et al., 2003) . Previous studies as well as our own have showed that nanoparticles passing through the alveolar-capillary barrier and penetrating into the blood circulation might lead to endothelial dysfunction, coagulation system disorders and so forth (Bai et al., 2007; Peters et al., 1999; Zhu et al., 2008) .
It is known that inhaled nanoparticles may be eliminated from lung tissue via four major routes (Oberdörster, 1988; Takenaka et al., 2001) . (1) be eliminated through the tracheobronchial tree, ingested into gastrointestinal tract and excreted in the feces; (2) be dissolved by macrophages phagocytosis with subsequent transfer into the blood; (3) pass through the alveolar wall with subsequent transfer into the blood; (4) translocate into lymph nodes.
Nanoparticles by virtue of their ultrafine size are likely to transport from lung into body circulation and thus influence the cardiovascular system directly (Geiser et al., 2005; Kato et al., 2003; Oberdörster et al., 2002) . In the present work, the fact that the 59 Fe 2 O 3 nanoparticles in blood could be rapidly detected within 10 min postinstillation demonstrated that part of the instilled 59 Fe 2 O 3 nanoparticles escaped from phagocytosis by alveolar macrophages and entered into blood circulation. It is hypothesized that ferric oxide nanoparticle could easily be dissolved during phagocytosis by macrophages. Thus RAW264.7 cells were used to study the dissolution of Fe 2 O 3 nanoparticles have been found to be quickly distributed in organs rich in mononuclear phagocytes, which was consistent with the findings of other undissolved nanoparticles, such as carbon nanoparticles and titanium oxide (Oberdörster et al., 2002; Wang et al, 2007) . The dissolution studies showed that during circulation and extrapulmonary distribution, only a limited amount of entered Fe 2 O 3 nanoparticles could be dissolved as iron ions in phagolysosomal simulant fluid and U937 monocytes lysosome (3.96% and 11.4%, respectively, Table 8 ).
The particokinetics in blood was consistent with onecompartment model (Fig. 2) , suggesting that 59 Fe 2 O 3 nanoparticles could easily pass through a number of tissue compartments and move freely and rapidly to target organs. Moreover, the long elimination half-life (22.8 days) and limited elimination constant (0.030/day) implied that long-course of 59 Fe 2 O 3 nanoparticles circulation in the body had occurred. Comparatively, the half-life of Fe 3þ or Fe 2þ ions was within several hours, which was far shorter than it was found in this study. These results indicating the dissolved iron was hardly contributed to the systemic distribution and metabolism studies. The only considered distinct organ was kidney because the free iron might probably excreted through urine, which meant the 59 Fe content in kidney was more likely to contain a larger percentage of iron ions.
Because iron is an essential element for normal cellular function and general health for the organisms, iron overload plays a pathologic role in certain cardiac disorders including hemochromatosis, beta-thalassemia and atherosclerosis (Brittenham et al., 1994; Horwitz and Rosenthal, 1999; Olson et al., 1987) . We previously demonstrated that the blood coagulation parameters were significantly disturbed as subacute responses by Fe 2 O 3 nanoparticles exposure. These responses were likely to involve free radical generation through the Fenton reaction, lipid peroxidation and inflammatory reactions induced by iron accumulation (Brittenham et al., 1994; Zhu et al., 2008) . The nanoparticles are so active that free radicals and inflammation are generated more than fine particles (Brown et al., 2001; Kuschner et al., 1997) , so the long half-life of elimination in blood is considered as an essential health risk mechanism for cardiovascular diseases.
The long elimination half-life may be attributed to two probable causes, one is that nano-59 Fe 2 O 3 retention in lung became a persistent source and released at an extremely slow speed, as the absorption half-life T 1/2 K01 was 1.9 days from the host lung tissue to blood and the clearance rate was 3.06 lg per day. Another is that nano-59 Fe 2 O 3 was prone to escape from detection and phagocytosis by monocytes/macrophages or hardly be cleared after phagocytosis during circulation.
The considerable aspect of the enhanced toxicity of nanoparticles was the prolonged retention time of particles in lung. The limited clearance rate (Park and Wexler, 2007; Scheuch et al., 1996) enhanced the deposition and accumulation in the deeper parts of the lung (Gehr et al., 1990) . In our study, the elimination rate of 59 Fe 2 O 3 nanoparticle in the lung was at an extremely slow speed of 3.06 lg/day (0.745& of original dose) from days 1 to 50 postinstillation. Moreover, in the histopathological examination, agglomerated nano-Fe 2 O 3 phagocytized by alveolar macrophages were frequently found at day 7, until postinstilled day 30, the phagocytized and undissolved Fe 2 O 3 nanoparticles could still be found in alveolar macrophages (Fig. 4) . Furthermore, in the TEM inspection, Fe 2 O 3 nanoparticles were frequently found in lung epitheliums at day 30 postinstillation, indicating the escaped Fe 2 O 3 nanoparticles from phagocytosis inserted into epitheliums and were hard to be (Hewitt, 1988) . The high concentration of iron was also observed in the lung of welders and workers using magnetopneumography (Kalliomaki et al. 1986 ). Our results supplied supportive evidences for iron accumulation in occupational diseases. Moreover, in our previous study, we had demonstrated the inflammatory reactions, oxidative stress and microvascular permeability increase could be induced in lungs by 22-nm-sized Fe 2 O 3 particles intratracheal instillation (Zhu et al., 2008) . It infers that these toxicological conditions would then reduce the tissue physiological clearance functions resulting in more severe cumulative toxicities. Once transferring into vessels from lungs, nanoparticles will be distributed into target organs specifically and selectively. Previous researches have demonstrated that reticuloendothelial system (RES), which has the function of taking up particular substances and be part of the body's defense system, will be the target organs of nanoparticle extrapulmonary translocation (Chen et al., 2006; Kim et al., 2006; Park et al., 2006 (Park and Wexler, 2007; Zhang et al., 2005) , and then go into gastrointestinal tract route. In our study, the aggregated 59 Fe 2 O 3 particles were eliminated through the tracheobronchial tree and subsequently excreted via gastrointestinal tract at days 1 and 2 postinstillation, acting as the behaviors of large particles. Similar results have been found by many researches after intratracheal instillation or inhalation of high concentration of UFP (Ferin et al., 1992; Hoet et al., 2004) . Considering the ID, the 4 mg/rat is assumed to be the worst case for cumulative exposure. As the method of intratracheal instillation brings a loss of instillation particle suspension, therefore, a high dose for toxic metabolism study has been chosen. However, we found that extremely limited amount of 0. Fe 2 O 3 in the lung tissue and the results of the blood metabolic particokinetics and lung clearance kinetics were mainly contributed from the behavior of these particles. The TEM images (Fig. 5) clearly showed that the Fe 2 O 3 nanoparticles had escaped from phagocytosis by alveolar macrophages and entered into alveolar epitheliums as well.
In conclusion, the metabolism study of radioactive Fe 2 O 3 in blood is consistent with the onecompartment model. The extrapulmonary target organs are mononuclear phagocyte-rich organs, such as liver, spleen, kidney and testicle. The extremely long elimination half-life in blood (22.8 day) and limited lung clearance rate (À3.06 lg/day) indicate that the systemic accumulation and lung retention has occurred, which may provide a favorable interpretation of the iron accumulation in lung by occupational and other long-term exposure. The avoidance of phagocytosis of Fe 2 O 3 nanoparticles by monocytes/macrophages and the dysfunction and obvious overloading of monocytes/macrophages clearance were supposed to be the crucial reasons for nanotoxicity. The long burdening of nano-Fe 2 O 3 may probably induce harmful clinic consequence in cardiorespiratory system including hemochromatosis, beta-thalassemia and coagulation system disorders by nano-Fe 2 O 3 high reactivities in free radical and inflammatory generation. Because the cumulative toxicity is indispensable in nanoparticles intentional and unintentional exposure, it is supposed that the potential health risk of low level of Fe 2 O 3 nanoparticles exposure in ambient air should be evaluated. Ingredients in phagolysosomal simulant fluid: Na 2 HPO 4 , 142 mg/l; NaCl, 6650 mg/l; Na 2 SO 4 , 71.0 mg/l; CaCl 2 2H 2 O, 29.0 mg/l; C 2 H 5 NO 2 , 450 mg/l; potassium hydrogen phthalate (1-(HO 2 C)-2-(CO 2 K)-C 6 H 4 , 4084 mg/l); pH ¼ 4.5 (Woodhall et al. 2003) . Ingredients in gastric fluid: NaCl, 2 g/l; 36.5% HCl, 7 ml/l; pepsin, 3.2 g/l, pH ¼ 1 .
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